Moleculin Biotech Updates Corporate Investor Presentation May 2026

Moleculin Biotech, Inc. filed a Form 8-K on May 26, 2026, to announce the release of an updated corporate investor presentation. The presentation, dated May 2026, was posted to the company's website and included as Exhibit 99.1 to the filing. This disclosure was made under Item 7.01 (Regulation FD Disclosure), which means the information is being furnished rather than filed and is not subject to the same liability provisions as filed documents, nor is it incorporated by reference into the company's previous Securities Act filings unless specifically stated. The filing serves as a routine update to provide current corporate information to the investment community and does not detail specific new clinical trial results, regulatory milestones, or financial transactions beyond the existence of the presentation itself. The company's common stock continues to trade on the NASDAQ Stock Market under the symbol MBRX. No upcoming trial result dates were specified in the narrative of the 8-K.